超速进化转流器的有效性和安全性:系统性审查和元分析
Seyed Behnam Jazayeri1, Abdullah Reda2, Jonathan Cortese3
1Tehran University of Medical Sciences, Tehran, Iran; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Clinical neurology and neurosurgery
|April 10, 2025
概括
超越进化流量转移器 (SE-FD) 在治疗内动脉瘤方面表现出中度的疗效,完全封闭率为67.1%. 支架狭窄是最常见的并发症,较大的动脉瘤大小与较低的闭塞率相关.
科学领域:
- 神经内血管治疗是一种神经内血管治疗.
- 脑血管疾病管理
- 医疗器械评估 医疗器械评估
背景情况:
- 内动脉瘤带来重大风险,需要有效的治疗选择.
- 流量转移器已经成为动脉瘤治疗的最小侵入性方法.
- 超越进化流量转换器 (SE-FD) 是一个在这种情况下使用的设备.
研究的目的:
- 综合现有关于SE-FD在内动脉瘤的安全性和有效性的证据.
- 评估与SE-FDs相关的完全闭塞率和并发症概况.
- 确定影响治疗结果的因素.
主要方法:
- 在主要数据库 (PubMed,Scopus,Embase,Web of Science) 中进行了系统的文献搜索.
- 使用元分析和元回归来汇集来自11项涉及690名患者的研究的数据.
- 主要结局包括完全封闭率和安全终点 (并发症,死亡率).
主要成果:
- 整体完全闭塞率为67.1% (95% CI:57.3-75.5%),破裂动脉瘤与未破裂动脉瘤之间没有显著差异.
- 支架狭窄症 (18.2%) 是最常见的并发症,其次是血栓栓塞事件 (6.6%) 和缺血性中风 (1.9%).
- 与设备相关的死亡率很低,为0.5%. 动脉瘤直径是较低闭塞率 (p < 0.001) 的显著预测指标.
结论:
- 在治疗内动脉瘤方面,SE-FD显示出适度的疗效和可接受的安全性.
- 更大的动脉瘤直径与治疗成功的减少有关.
- 建议进行进一步的受控研究,以充分阐明SE-FDs的长期疗效和安全性.
相关概念视频
Mitral Valve Prolapse II: Assessment and Management
1.4K
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.4K
Mitral Regurgitation III: Medical Management
689
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
689
Mitral Stenosis III: Medical Management
538
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
538
Aortic Regurgitation III: Medical Management
598
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
598
Urodynamic Studies: Uroflowmetry
9.5K
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
9.5K


